HK Stock Market Move | MICOT PHARMA-B (02335) rose over 5%, recently included in the stock list under the Stock Connect mechanism, Phase II clinical trial of MT200605 completed.

MICOT PHARMA-B (02335) rose over 5% during intraday trading, up 5.67% as of press time, at HK$21.98, with a turnover of HK$1.182 million. On the news front, MICOT PHARMA-B announced that, according to announcements published by the Shanghai Stock Exchange and the Shenzhen Stock Exchange on September 4, 2026 and September 7, 2026 respectively, the company's H shares have been included in the list of eligible shares under the Stock Connect mechanism (Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect), effective from September 7, 2026. Following the inclusion of the shares in the Stock Connect mechanism, eligible mainland Chinese investors can trade the shares through the Shanghai Stock Exchange and the Shenzhen Stock Exchange. Previously, MICOT PHARMA-B announced that the Phase II clinical trial of MT200605, a candidate drug independently developed by the group for the treatment of acute ischemic stroke, has been completed. The clinical trial has demonstrated significant and robust efficacy advantages and a favorable safety profile.